
Enhanced Mobilisation Service
NHS biosimilar switching
Join the NHS Trusts and Health Boards across the UK who have chosen Sciensus to manage their programmes and patient and biosimilar transitions.
How does the Sciensus NHS biosimilar switching service work?
In a landscape where capacity is more of a concern than ever, transitioning patients to an alternative medicine can significantly reduce NHS workload. Sciensus makes migrating patients between products or service provider easy. The Sciensus NHS biosimilar switching process was developed using feedback from our NHS partners, to now offer innovative, digitally enabled solutions to specifically decrease the demand and the administrative burden on the NHS and manage their biosimilar switch with ease.
Since 2018, Sciensus have had a dedicated Mobilisation Team to support with conducting NHS biosimilar switching and provider switches. Within 12 months, Sciensus migrated over 40,000 patients, met NHS cost saving targets, minimised workload and delivered a seamless patient experience. Sciensus has continued to develop our NHS offering in line with the changing requirements of the NHS and their patients.

How can you and your team benefit from using Sciensus Mobilisation Service?
- A seamless experience when switching to an alternative medicine
- Automated processes and support from Sciensus non-medical prescribers to reduce administrative burden
- Expedited switch to allow patients to transition to more cost-effective medicines sooner
- Streamlined Sciensus onboarding capability allows multiple Trusts to switch at pace simultaneously
- Market-leading proposition achieved through collaborative work between Sciensus and the NHS to deliver valuable, innovative solutions and increase market share
Ustekinumab biosimilar switch delivers immediate savings and streamlined patient support
Gloucestershire Hospitals NHS Foundation Trust (GHFT) partnered with Sciensus in 2024 on their switch to a ustekinumab biosimilar. By working with Sciensus, GHFT was able to ensure rapid uptake, strong patient engagement and measurable cost savings, with no added burden on clinical teams.
Patients were informed of the change and supported through clinical assessments, blood tests and access to clinician-led training. Behind the scenes, Sciensus delivered an automated prescribing pathway with pre-populated continuation prescriptions generated for eligible patients. These were clinically screened and signed by Sciensus’ non-medical prescribers, removing the need for further involvement from the GHFT team.
With a clear support process in place for patients and no additional admin required from the Trust, the switch was delivered efficiently and savings were realised immediately.
It is an amazing service Sciensus have put together, it has been a well-run, organised offering, that has done exactly what it set out to do.
Kathrine Wood, Pharmacy Homecare Services Manager
Get in touch
Thank you for your interest in Sciensus. Whether you’re seeking information, partnership opportunities, or want to refer a patient, our dedicated team is here to assist you. Please fill out the form on the right, and one of our multi-lingual representatives will get in touch with you promptly.
Read more about…

Events
ASCO 2025
Sciensus will be attending the upcoming ASCO (American Society of Clinical Oncology). ASCO is one of the most influential events…

News
Sciensus achieves 95% patient satisfaction and record NPS
At Sciensus, delivering life-changing therapies is more than a service — it’s a commitment to the people behind every prescription.…

Blogs
Driving reimbursement success in Europe with real-world data
Andrew Cummins, Vice President Business Development, and Mathieu Loiseau, Director of Rare Clinical Services, spoke at the recent World Orphan…